No Data
Noble Financial Maintains GeoVax Labs(GOVX.US) With Buy Rating, Raises Target Price to $12
GeoVax Labs (GOVX) Receives a Buy From Noble Financial
GeoVax Labs' Promising Vaccine Trials Enhance Buy Rating Amid Robust Immune Response and Market Potential
GeoVax Labs Announces Interim Data From Phase 2 Trial of Vaccine Technology
Express News | GeoVax Labs Inc - Dsmb Recommends Continuation of Geo-Cm04S1 Vaccine Trial
Express News | GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
